What is it? Why is it important?

Good Manufacturing Practice (GMP) describe processes that ensure that:

  • Therapeutic Products (TP) are produced in a consistent manner.
  • Production procedures with its quality standards, are subject to ongoing quality controls with respect to the TP`s intended use
  • The management of product defects and complaints of authorised Medicinal Products (MP) works in a feedback loop manner

 

Processes must be clearly defined, reviewed for applicability, and diligently documented. The ongoing documentation during TP production is paramount in order to prove to Regulatory Authorities (RA) (e.g. Swissmedic) that production and quality standards were complied with. Swissmedic inspects TP production sites in the context of a TP marketing approval application.

 

Personnel responsible for the production and quality assurance must:

  • Comply with the required GMP standards
  • Have the required skills and trainings

 

Once approved by Swissmedic, Good Distribution Practices (GDP) come into effect (access additional information under "More")

More

Compliance with Good Distribution Practices (GDP) ensure that the Medical Product (MP):

  • Supply chain is authorised in accordance with RA legislations (e.g. Swissmedic, EU)
  • Is transported and stored according to defined requirements (e.g. acceptable timelines, temperature, light and humidity exposure, vibration and access protected)
  • Is protected against contamination by other products
  • Reaches the right addressee
  • Has an adequate turnover

 

MP distributors should have an effective tracing system in place, enabling finding faulty MP products including the implementation of required recall procedures.

GDP also address the sourcing, storage and transportation of active pharmaceutical ingredients and other ingredients used in the production of MPs.

What do I need to do?

As a SP-INV and Site-INV, make yourself familiar with GMP and GDP guidelines and their applicability and requirements during study planning and conduct, such as:

  • GMP requirements in the production of a placebo product used in an interventional blinded study
  • Transport, storage and access requirements of a Medical Product (MP)
  • Documentation needed to confirm compliance with GMP and GDP requirements

 

Note: The “Drug & Device” section addresses Medicinal Products and Medical Devices. “In Vitro Medical Devices” are not discussed in the Easy-GCS.

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

External Links

Swissmedic – see in particular

  • Human medicines / licensing / authorisation / Certificates
  • Latest news / general communication / access Consortium statement

References

ICH GCP E6(R3) – see in particular guidelines and glossary

  • 11. Investigational products should be manufactured in accordance with GMP standards
  • 3.15.2 Manufacturing, packaging, labelling, coding
  • Glossary: Investigational product definition

Swiss Law

TPA – see in particular articles

  • Art. 4 Medicinal Product (MP) definition
  • Art. 4 Distribution / dispensing definition
  • Art. 7 Manufacturing standards (GMP)
  • Art. 29 Wholesale standards (GDP)
  • Art. 58 Official market surveillance

MPLO  Medicinal Products Licensing Ordinance – see in particular articles

  • Art. 1 Object and definitions
  • Art. 4 Responsibility and GMP
  • Art. 13 Market release
Abbreviations
  • CTU – Clinical Trials Unit
  • EU – European Union
  • GDP – Good Distribution Practice
  • GMP – Good Manufacturing Practice
  • ICH GCP – International Council for Harmonisation - Good Clinical Practice
  • MPLO – Medicinal Products Licensing Ordinance
  • MP – Medicinal Product
  • MD – Medical Device
  • RA – Regulatory Authorities
  • Site-INV – Site-Investigator
  • SP-INV – Sponsor
  • TP – Therapeutic Product
  • TPA – Therapeutic Product Act
Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Good Manufacturing Practice
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Drug or Device ↦ Therapeutic Products ↦ Good Manufacturing Practice

Please note: the Easy-GCS tool is currently under construction.